Table 1 Characteristics of SLE patients used for analysis
From: A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus
Number | 47 |
|---|---|
Age, year | 42.4 ± 14.8 |
Female, number (%) | 33 (70) |
SLEDAI | 5.0 ± 4.8 |
CH50, U/mL | 31.7 ± 12.0 |
Anti-dsDNA antibody, U/mL | 105.0 ± 134.2 |
CRP, mg/dL | 0.4 ± 0.9 |
Organ manifestations | |
 Skin, number (%) | 11 (23.4) |
 Arthritis, number (%) | 10 (21.3) |
 Cytopenia, number (%) | 18 (38.3) |
 Lupus nephritis, number (%) | 20 (42.5) |
 Serositis, number (%) | 7 (14.9) |
Immunosuppressive therapy | |
 Prednisolone, mg/day | 10.9 ± 9.6 |
 Azathioprine, number (%) | 10 (21.3) |
 Methotrexate, number (%) | 9 (19.1) |
 Tacrolimus, number (%) | 12 (25.6) |
 Cyclosporine, number (%) | 4 (8.5) |
 Hydroxychloroquine, number (%) | 0 (0) |